SRSF2 and acquired polycythemia vera: In the study of PV patients, they observed a higher risk of fibrotic progression in patients with additive mutations such as DNMT3A, IDH2, SRSF2, or U2AF1, however mutations in TET2 were not implicated in disease progression [89].